Lilly Executive and Leadership Team

Pandurang Kulkarni, the Chief Executive Officer, Aparito, Chief Analytics Officer, Research Developmment & Senior VP Stats, Data, & Analytics at Lilly, directs the integration of advanced data science into the biopharmaceutical discovery pipeline. Kulkarni architects complex statistical frameworks that accelerate the development of prescription medicines. By overseeing the intersection of clinical data and digital health, the Chief Analytics Officer ensures that research initiatives maintain high precision across global markets. This leadership role involves managing large-scale data infrastructure to support breakthroughs in oncology and immunology. Pandurang Kulkarni drives the adoption of predictive modeling to optimize clinical trial outcomes. Through the application of rigorous statistical methodologies, the Senior VP Stats, Data, & Analytics enhances the efficiency of the entire research and development lifecycle, ultimately securing a competitive advantage for the firm in the international pharmaceutical landscape.

Marija Popovic, the Global Chief Operating Officer, Statistical Sciences & Advanced Analytics at Lilly, oversees the operational execution of statistical research and advanced analytical programs. Popovic directs the deployment of sophisticated data models that inform the development of new prescription medicines. By managing the global operations of the statistical sciences division, the Global Chief Operating Officer ensures that research methodologies meet rigorous international standards. This leadership role involves coordinating with cross-functional teams to translate complex data into actionable insights for the oncology and neuroscience portfolios. Marija Popovic drives the implementation of scalable analytical tools that enhance the speed and accuracy of clinical development. Through the optimization of research operations, the Global Chief Operating Officer supports the firm's commitment to innovation, ensuring that data-driven decision-making remains at the heart of the company's global biopharmaceutical strategy.

Tobias Gustavsson, the Chief Operating Officer, & Zealand (Australia) at Lilly, directs the commercial and operational activities across the Australian and regional markets. Gustavsson manages the distribution and market access strategies for prescription medicines within this geographic territory. By overseeing the local supply chain and commercial operations, the Chief Operating Officer ensures that patients receive timely access to critical treatments in diabetes and oncology. This leadership role involves navigating regional regulatory environments to maintain compliance and market growth. Tobias Gustavsson executes business development plans that expand the firm's presence in the region. Through the coordination of local sales and operational teams, the Chief Operating Officer drives revenue growth and strengthens the company's market position, ensuring that the regional operations align with the global commitment to delivering high-quality biopharmaceutical solutions to patients.

Scott Booziotis, the Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer at Lilly, manages the operational strategy for early-stage clinical programs within the oncology division. Booziotis directs the medical affairs team to ensure that clinical data effectively supports the development of new cancer therapies. By overseeing the operational aspects of early-phase trials, the Chief Operating Officer facilitates the transition of research discoveries into viable prescription medicines. This leadership role involves collaborating with clinical researchers and regulatory bodies to advance the oncology pipeline. Scott Booziotis executes strategic plans that prioritize patient safety and therapeutic efficacy in the early stages of drug development. Through the integration of medical expertise and operational oversight, the Executive Director strengthens the firm's position in the competitive oncology market, ensuring that innovative treatments reach clinical milestones efficiently.

LisaAnn Trembath, the Chief Operating Officer, Global Imaging at Lilly, directs the operational strategy for the company's global imaging initiatives. Trembath manages the integration of advanced imaging technologies into the clinical development process for prescription medicines. By overseeing the global operations of the imaging division, the Chief Operating Officer ensures that diagnostic tools support the accurate assessment of therapeutic efficacy in oncology and neuroscience. This leadership role involves coordinating with research teams to standardize imaging protocols across international clinical trials. LisaAnn Trembath executes operational plans that enhance the precision of drug development through high-quality diagnostic data. Through the optimization of imaging workflows, the Chief Operating Officer supports the firm's commitment to research-driven innovation, ensuring that the company maintains a leading edge in the development of targeted therapies through superior diagnostic capabilities.

Elizabeth van Gelder, the Senior Director, Information Technology & Business Units & Special Projects Chief of Staff at Lilly, manages the alignment of digital infrastructure with core business unit objectives. van Gelder coordinates cross-functional special projects that streamline internal processes and enhance operational agility. By overseeing the integration of information technology systems, the Senior Director ensures that business units maintain seamless connectivity across international operations. This leadership role involves facilitating communication between technical teams and executive leadership to drive strategic initiatives forward. Elizabeth van Gelder executes complex project roadmaps that support the discovery and commercialization of prescription medicines. Through the optimization of internal workflows, the Chief of Staff strengthens the organizational capacity to respond to evolving market demands in the biopharmaceutical sector, ensuring that technology investments directly contribute to the overarching mission of improving patient outcomes.

Tracy Huang, the Senior Secretary To Chief Information Officer at Lilly, coordinates the administrative operations and strategic scheduling for the information technology leadership team. Huang manages the flow of critical information between the Chief Information Officer and various departments, ensuring that technical priorities remain aligned with corporate goals. By overseeing the logistical requirements of the IT division, the Senior Secretary facilitates the smooth execution of digital transformation projects. This leadership role involves maintaining high-level oversight of departmental communications and resource allocation. Tracy Huang supports the development of robust IT strategies that underpin the manufacturing and commercialization of prescription medicines. Through the meticulous management of executive workflows, the Senior Secretary enables the Chief Information Officer to focus on scaling the firm's global digital infrastructure, thereby contributing to the overall efficiency and technological advancement of the biopharmaceutical enterprise.

Kushal Vanga, the Director - Chief of Staff (LRL Bengaluru) at Lilly, manages the operational strategy and administrative coordination for the research laboratories in the region. Vanga directs the alignment of local research activities with the broader global biopharmaceutical mission. By overseeing the daily operations of the Bengaluru facility, the Director ensures that scientific teams possess the necessary resources to advance the discovery of prescription medicines. This leadership role involves facilitating collaboration between regional research units and global headquarters to maintain consistency in development standards. Kushal Vanga executes strategic initiatives that optimize laboratory performance and foster innovation in immunology and diabetes research. Through the effective management of regional operations, the Chief of Staff supports the firm's international research footprint, ensuring that the Bengaluru site contributes significantly to the overall success of the company's drug development pipeline.

Hongyun Zhao, the Advisor, Bioanalysis and Chief Revenue Officer Management at Lilly, directs the analytical processes required for bioanalysis while overseeing revenue management strategies. Zhao manages the financial implications of research outcomes, ensuring that bioanalytical data supports the commercial viability of new prescription medicines. By overseeing the intersection of scientific analysis and revenue planning, the Advisor ensures that the firm maximizes the value of its drug development portfolio. This leadership role involves providing strategic guidance on the financial impact of clinical findings in immunology and neuroscience. Hongyun Zhao executes revenue management frameworks that optimize the commercialization of the company's therapeutic offerings. Through the application of rigorous analytical standards, the Chief Revenue Officer Management supports the firm's financial health, ensuring that research investments translate into sustainable growth and long-term market success.

Christina Vega, the VP-Head of Immunology, Oncology, and Neuroscience Division and Chief Marketing Officer at Lilly, directs the global marketing and commercial strategy for the firm's core therapeutic areas. Vega manages the brand positioning and market penetration for prescription medicines in immunology, oncology, and neuroscience. By overseeing the development of comprehensive marketing campaigns, the Chief Marketing Officer ensures that healthcare providers and patients understand the value of the company's innovative treatments. This leadership role involves coordinating with research and development teams to align product launches with clinical breakthroughs. Christina Vega executes strategic initiatives that drive market share growth across international territories. Through the integration of scientific messaging and commercial strategy, the VP-Head of Immunology, Oncology, and Neuroscience Division strengthens the firm's market presence, ensuring that life-changing therapies reach the patients who need them most.